Anavex Announces Executive Overseeing Regulatory Affairs
November 25 2015 - 8:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing drug candidates to treat Alzheimer’s disease, other
central nervous system (CNS) diseases, pain and various types of
cancer, announces that Kristina M. Capiak, CCRP has been promoted
the Company’s Vice President of Regulatory Affairs. She is
overseeing U.S. and international regulatory matters for Anavex,
including filings and interactions with the FDA and other
regulatory authorities.
“We are excited to expand Ms. Capiak’s role to
oversee the Company’s clinical development programs and other
indications given Ms. Capiak’s expertise and we are delighted to
have her on our team,” said Dr. Christopher U. Missling, PhD,
President and Chief Executive Officer for Anavex.
Ms. Capiak has more than 10 years of academic
clinical research and healthcare industry experience within the
biotech industry. Prior to joining Anavex, Ms. Capiak was the
Global Regulatory Lead at Retrophin, Inc. where she implemented
U.S. and EU strategy for the ongoing development programs, which
received orphan drug designations as well as fast track
designation. At Regeneron Pharmaceuticals Ms. Capiak was on
the pharmacovigilance and risk management team where she analyzed
the ongoing safety events for the pipeline of development products
and for EYLEA®.
Ms. Capiak’s background also includes clinical
trial staffing and oversight for more than 60 clinical trials at
both Columbia University Medical Center, where she co-authored
several papers, and Memorial Sloan-Kettering Cancer Center, where
she became a Certified Clinical Research Professional (CCRP)
through the Society of Clinical Research Associates.
While an undergraduate, Ms. Capiak participated
in translational medical research at the University of Michigan
Medical School through the Undergraduate Research Opportunity
Program. She is a graduate of both the University of Michigan
and New York City’s Columbia University.
About Anavex Life Sciences
Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel drug candidates to treat central nervous
system (CNS) diseases and various types of cancer. Anavex’s lead
drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of
ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a
clinical trial for Alzheimer’s disease. The drug combination ANAVEX
PLUS produced up to 80% greater reversal of memory loss in
Alzheimer’s disease models versus when the drugs were used
individually. ANAVEX 2-73 is an orally available drug candidate
that targets sigma-1 and muscarinic receptors and successfully
completed Phase 1 with a clean data profile. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer’s disease. It has also exhibited anticonvulsant,
anti-amnesic, neuroprotective and anti-depressant properties in
convulsive epileptic animal models, indicating its potential to
treat additional CNS disorders, including epilepsy and others.
Michael J. Fox Foundation (MJFF) for Parkinson’s Research has
awarded Anavex a research grant to develop ANAVEX 2-73 for the
treatment of Parkinson’s disease to fully fund a preclinical study,
which could justify moving ANAVEX 2-73 into a Parkinson’s disease
clinical trial. Further information is available at
www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Shareholder & Media Relations
Toll-free: 1-866-505-2895
Outside North America: +1 (416) 489-0092
Email: ir@anavex.com
www.anavex.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024